ProtoKinetix, Inc. announced significant leadership changes, including the resignation of Edward McDonough and the appointment of Michael Jones, Jason Lamp, and Dr. Keith Brunt as directors. Dr. Brunt was also named president. The company formed SightPath Biotech LLC, a wholly-owned subsidiary, to develop its PKX-001 molecule for dry-eye disease, with related patents valued at approximately $253 million. Additionally, ProtoKinetix repriced 61.19 million stock options and 6 million warrants to an exercise price of $0.01 per share and extended their expiration dates. The company also noted late filings for its 2025 10-K and 2026 Q1 10-Q.
